First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors

• Status: Completed
• Trial end date: 2004-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study was to characterize the safety of investigational agent AG-013736, in patients with solid tumors in this First In Human trial.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Axitinib

Criteria

Inclusion Criteria:

• Patients with cytologically or histologically confirmed solid tumor(s) and with at least one measurable disease site

• Patients with adequate bone marrow, liver and kidney function

• Patients with life expectancy of at least 12 weeks

Exclusion Criteria:

• Patients who have received chemotherapy, immunotherapy, radiotherapy or any investigational agent within 4 weeks of study entry

• Patients with have had a major surgical procedure within 4 weeks of study entry